Elissa M. Ozanne

Elissa M. Ozanne, PhD

Languages spoken: English

Academic Information

Departments Primary - Population Health Sciences

Research Interests

  • Cost Effectiveness Analysis
  • Developing and Evaluating Methods to Improve Patient and Provider Decision Making
  • Developing and Evaluating Risk Assessment and Communication Strategies
  • Decision Analysis

A decision scientist and health services researcher, Dr. Ozanne’s research focuses on patient-centered use of prevention, screening, and treatment strategies in medicine. Dr. Ozanne serves as principal investigator of several National Cancer Institute (NCI), American Heart Association (AHA), and Patient-Centered Outcomes Research Institute (PCORI) grants studying novel approaches for access to, and evaluation of, patient-centered care. She has published more than 100 articles. Dr. Ozanne is the Co-director of the Graduate Certificate in Population Health Sciences.

Prior to moving to Utah, Dr. Ozanne worked at the Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth, the Institute for Health Policy Studies at the UCSF, and the Institute for Technology Assessment at Massachusetts General Hospital and Harvard Medical School.

Dr. Ozanne earned her Ph.D. from Stanford University in Management Science and Engineering. She received a M.S. in Engineering Economic Systems and a B.S. in Biological Sciences also from Stanford University.

Research Statement

Dr. Elissa Ozanne's primary career goal is to guide effective, patient-centered use of prevention, screening, and treatment strategies in cancer and other contexts. Her research is focused on decision-making, including the developing and testing of clinical decision aids, risk communication methods, cost-effectiveness and risk modeling.

Education History

Postdoctoral Training Harvard Medical School
 Postdoctoral Training
Dartmouth-Hitchcock Medical Center
 Postdoctoral Training
Postdoctoral Training Massachusetts General Hospital
 Postdoctoral Training
University of California, San Francisco
 Postdoctoral Training
Doctoral Training Stanford University
 PhD
Stanford University
 MS
Undergraduate Stanford University
 BS

Selected Publications

Journal Article

  1. Wang T, Che M, Huilgol YS, Keane H, Goodman D, Soonavala R, Ozanne E, Shieh Y, Belkora JK, Fiscalini AS, Athena Breast Health Network Investigators and Advocate Partners, Esserman LJ (2024). Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study. NPJ Breast Cancer, 10(1), 90. (Read full article)
  2. Ozanne EM, Maves K, Tramontano AC, Lynch T, Thompson A, Partridge A, Frank E, Collyar D, Basila D, Pinto D, Hyslop T, Ryser MD, Rosenberg S, Hwang ES, Punglia RS (2024). Impact of an online decision support tool for ductal carcinoma in situ (DCIS) using a pre-post design (AFT-25). Breast Cancer Res, 26(1), 134. (Read full article)
  3. Zhong L, Rodriguez Y, Espinel W, Ozanne EM, Kaphingst KA (2024). Investigating genetic counselors' communication with Lynch syndrome patients about cascade testing: Barriers, facilitators, and strategies. J Genet Couns. (Read full article)
  4. Leonard ME, Horns JJ, Allen-Brady K, Ozanne EM, Wallace AS, Brooke BS, Supiano MA, Cohan JN (2024). Recurrence of severe diverticulitis is associated with age and birth decade. J Gastrointest Surg, 28(4), 507-512. (Read full article)
  5. Thorpe A, Delaney RK, Pinto NM, Ozanne EM, Pershing ML, Hansen LM, Lambert LM, Fagerlin A (2023). Parents' Psychological and Decision-Making Outcomes following Prenatal Diagnosis with Complex Congenital Heart Defect: An Exploratory Study. MDM Policy Pract, 8(2), 23814683231204551. (Read full article)
  6. Jones AE, McCarty MM, Cameron KA, Cavanaugh KL, Steinberg BA, Passman R, Kansal P, Guzman A, Chen E, Zhong L, Fagerlin A, Hargraves I, Montori VM, Brito JP, Noseworthy PA, Ozanne EM (2023). Development of Complementary Encounter and Patient Decision Aids for Shared Decision Making about Stroke Prevention in Atrial Fibrillation. MDM Policy Pract, 8(1), 23814683231178033. (Read full article)
  7. Delaney RK, Thorpe A, Pinto NM, Ozanne EM, Pershing ML, Hansen LM, Lambert LM, Tanner K, Fagerlin A (2023). Parents' quality of life and health after treatment decision for a fetus with severe congenital heart defect. J Pediatr Nurs, 70, 20-25. (Read full article)
  8. Jones AE, McCarty MM, Brito JP, Noseworthy PA, Cavanaugh KL, Cameron KA, Barnes GD, Steinberg BA, Witt DM, Crossley GH, Passman R, Kansal P, Hargraves I, Schmidt M, Jackson E, Guzman A, Ariotti A, Pershing ML, Herrick J, Montori VM, Fagerlin A, Ozanne EM, STEP-UP AFIB Writing Group (2022). Randomized evaluation of decision support interventions for atrial fibrillation: Rationale and design of the RED-AF study. Am Heart J, 248, 42-52. (Read full article)
  9. Delaney RK, Pinto NM, Ozanne EM, Stark LA, Pershing ML, Thorpe A, Witteman HO, Thokala P, Lambert LM, Hansen LM, Greene TH, Fagerlin A (2021). Study protocol for a randomised clinical trial of a decision aid and values clarification method for parents of a fetus or neonate diagnosed with a life-threatening congenital heart defect. BMJ Open, 11(12), e055455. (Read full article)
  10. Rogers AM, Lauren BN, Woo Baidal JA, Ozanne EM, Hur C (2021). Persistent effects of the COVID-19 pandemic on diet, exercise, risk for food insecurity, and quality of life: A longitudinal study among U.S. adults. Appetite, 167, 105639. (Read full article)
  11. Pinto NM, Patel A, Delaney RK, Donofrio MT, Marino BS, Miller S, Ozanne EM, Zickmund SL, Karasawa MH, Pershing ML, Fagerlin A (2021). Provider insights on shared decision-making with families affected by CHD. Cardiol Young, 1-8. (Read full article)
  12. Kaplan CP, Karliner L, Lee A, Livaudais-Toman J, Tice JA, Ozanne E (2021). Acceptability of an mHealth breast cancer risk-reduction intervention promoting risk assessment, education, and discussion of risk in the primary care setting. Mhealth, 7, 54. (Read full article)
  13. Cohan JN, Ozanne EM, Hofer RK, Kelly YM, Kata A, Larsen C, Finlayson E (2021). Ileostomy or ileal pouch-anal anastomosis for ulcerative colitis: patient participation and decisional needs. BMC Gastroenterol, 21(1), 347. (Read full article)
  14. Delaney RK, Pinto NM, Ozanne EM, Brown H, Stark LA, Watt MH, Karasawa M, Patel A, Donofrio MT, Steltzer MM, Miller SG, Zickmund SL, Fagerlin A (2021). Parents' decision-making for their foetus or neonate with a severe congenital heart defect. Cardiol Young, 32(6), 1-8. (Read full article)
  15. Keane H, Huilgol YS, Shieh Y, Tice JA, Belkora J, Sepucha K, Shibley WP, Wang T, Che M, Goodman D, Ozanne E, Fiscalini AS, Esserman LJ (2021). Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial. NPJ Breast Cancer, 7(1), 78. (Read full article)
  16. Baucom KJW, Pershing ML, Dwenger KM, Karasawa M, Cohan JN, Ozanne EM (2021). Barriers and Facilitators to Enrollment and Retention in the National Diabetes Prevention Program: Perspectives of Women and Clinicians Within a Health System. Womens Health Rep (New Rochelle), 2(1), 133-141. (Read full article)
  17. Trevena LJ, Bonner C, Okan Y, Peters E, Gaissmaier W, Han PKJ, Ozanne E, Timmermans D, Zikmund-Fisher BJ (2021). Current Challenges When Using Numbers in Patient Decision Aids: Advanced Concepts. Med Decis Making, 41, 272989X21996342. (Read full article)
  18. Bonner C, Trevena LJ, Gaissmaier W, Han PKJ, Okan Y, Ozanne E, Peters E, Timmermans D, Zikmund-Fisher BJ (2021). Current Best Practice for Presenting Probabilities in Patient Decision Aids: Fundamental Principles. Med Decis Making, 41, 272989X21996328. (Read full article)
  19. Durand MA, Yen RW, OMalley AJ, Schubbe D, Politi MC, Saunders CH, Dhage S, Rosenkranz K, Margenthaler J, Tosteson ANA, Crayton E, Jackson S, Bradley A, Walling L, Marx CM, Volk RJ, Sepucha K, Ozanne E, Percac-Lima S, Bergin E, Goodwin C, Miller C, Harris C, Barth RJ Jr, Aft R, Feldman S, Cyr AE, Angeles CV, Jiang S, Elwyn G (2020). What matters most: Randomized controlled trial of breast cancer surgery conversation aids across socioeconomic strata. Cancer, 127(3), 422-436. (Read full article)
  20. Lauren BN, Silver ER, Faye AS, Rogers AM, Woo Baidal JA, Ozanne EM, Hur C (2021). Predictors of households at risk for food insecurity in the United States during the COVID-19 pandemic. Public Health Nutr, 24, 1-19. (Read full article)
  21. Cohan JN, Orleans B, Brecha FS, Huang LC, Presson A, Fagerlin A, Ozanne EM (2021). Factors Associated With Decision Regret Among Patients With Diverticulitis in the Elective Setting. J Surg Res, 261, 159-166. (Read full article)
  22. Delaney RK, Sisco-Taylor B, Fagerlin A, Weir P, Ozanne EM (2020). A systematic review of intensive outpatient care programs for high-need, high-cost patients. Transl Behav Med, 10(5), 1187-1199. (Read full article)
  23. Sharib J, Esserman L, Koay EJ, Maitra A, Shen Y, Kirkwood KS, Ozanne EM (2020). Cost-effectiveness of consensus guideline based management of pancreatic cysts: The sensitivity and specificity required for guidelines to be cost-effective. Surgery, 168(4), 601-609. (Read full article)
  24. Brecha FS, Ozanne EM, Esplin J, Stoddard GJ, Nirula R, Huang LC, Cohan JN (2020). Patient Willingness to Accept Antibiotic Side Effects to Reduce SSI After Colorectal Surgery. J Surg Res, 261, 417-422. (Read full article)
  25. Ozanne EM, Soeteman DI, Frank ES, Clarke J, Hassett MJ, Stout NK, Punglia RS (2020). Commentary: Creating a patient-centered decision aid for ductal carcinoma in situ. Breast J, 26(7), 1498-1499. (Read full article)
  26. Barr PJ, Forcino RC, Thompson R, Ozanne EM, Arend R, Castaldo MG, OMalley AJ, Elwyn G (2017). Evaluating CollaboRATE in a clinical setting: analysis of mode effects on scores, response rates and costs of data collection. BMJ Open, 7(3), e014681. (Read full article)
  27. Punglia RS, Cronin AM, Uno H, Stout NK, Ozanne EM, Greenberg CC, Frank ES, Schrag D (2017). Association of Regional Intensity of Ductal Carcinoma In Situ Treatment With Likelihood of Breast Preservation. JAMA Oncol, 3(1), 101-104. (Read full article)
  28. Ozanne EM, Weiss JE, Onega T, DeMartini W, Kerlikowske K, Buist DS, Henderson L, Hubbard RA, Goodrich M, Tosteson AN, Virnig BA, ODonoghue C (2017). Locoregional treatment of breast cancer in women with and without preoperative magnetic resonance imaging. Am J Surg, 213(1), 132-139.e2. (Read full article)
  29. Barnes AJ, Hanoch Y, Miron-Shatz T, Ozanne EM (2016). Tailoring risk communication to improve comprehension: Do patient preferences help or hurt? Health Psychol, 35(9), 1007-16. (Read full article)
  30. Cohan JN, Ozanne EM, Sewell JL, Hofer RK, Mahadevan U, Varma MG, Finlayson E (2016). A Novel Decision Aid for Surgical Patients with Ulcerative Colitis: Results of a Pilot Study. Dis Colon Rectum, 59(6), 520-8. (Read full article)
  31. Barlow DR, Higgins BT, Ozanne EM, Tosteson AN, Pearson AM (2016). Cost Effectiveness of Operative Versus Non-Operative Treatment of Geriatric Type-II Odontoid Fracture. Spine (Phila Pa 1976), 41(7), 610-7. (Read full article)
  32. Hanoch Y, Miron-Shatz T, Rolison JJ, Omer Z, Ozanne E (2015). Shared decision making in patients at risk of cancer: the role of domain and numeracy. Health Expect, 18(6), 2799-810. (Read full article)
  33. Ozanne EM, Schneider KH, Soeteman D, Stout N, Schrag D, Fordis M, Punglia RS (2015). onlineDeCISion.org: a web-based decision aid for DCIS treatment. Breast Cancer Res Treat, 154(1), 181-90. (Read full article)
  34. Howe R, Miron-Shatz T, Hanoch Y, Omer ZB, ODonoghue C, Ozanne EM (2015). Personalized Medicine Through SNP Testing for Breast Cancer Risk: Clinical Implementation. J Genet Couns, 24(5), 744-51. (Read full article)
  35. Winn K, Ozanne E, Sepucha K (2015). Measuring patient-centered care: An updated systematic review of how studies define and report concordance between patients' preferences and medical treatments. Patient Educ Couns, 98(7), 811-21. (Read full article)
  36. Yachimski P, Wani S, Givens T, Howard E, Higginbotham T, Price A, Berman K, Hosford L, Katcher PM, Ozanne E, Perzan K, Hur C (2015). Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with Barrett's esophagus. Clin Gastroenterol Hepatol, 13(1), 84-90. (Read full article)
  37. Miron-Shatz T, Hanoch Y, Katz BA, Doniger GM, Ozanne EM (2015). Willingness to test for BRCA1/2 in high risk women: Influenced by risk perception and family experience, rather than by objective or subjective numeracy? Judgm Decis Mak, 10(4), 386-99.
  38. Hanoch Y, Miron-Shatz T, Rolison JJ, Ozanne E (2014). Understanding of BRCA1/2 genetic tests results: the importance of objective and subjective numeracy. Psychooncology, 23(10), 1142-8. (Read full article)
  39. Fehniger J, Livaudais-Toman J, Karliner L, Kerlikowske K, Tice JA, Quinn J, Ozanne E, Kaplan CP (2014). Perceived versus objective breast cancer risk in diverse women. J Womens Health (Larchmt), 23(5), 420-7. (Read full article)
  40. Esserman LJ, Alvarado MD, Howe RJ, Mohan AJ, Harrison B, Park C, ODonoghue C, Ozanne EM (2014). Application of a decision analytic framework for adoption of clinical trial results: are the data regarding TARGIT-A IORT ready for prime time? Breast Cancer Res Treat, 144(2), 371-8. (Read full article)
  41. ODonoghue C, Eklund M, Ozanne EM, Esserman LJ (2014). Aggregate cost of mammography screening in the United States: comparison of current practice and advocated guidelines. Ann Intern Med, 160(3), 145. (Read full article)
  42. Walsh T, Barr PJ, Thompson R, Ozanne E, ONeill C, Elwyn G (2014). Undetermined impact of patient decision support interventions on healthcare costs and savings: systematic review. BMJ, 348, g188. (Read full article)
  43. Ozanne EM, Howe R, Omer Z, Esserman LJ (2014). Development of a personalized decision aid for breast cancer risk reduction and management. BMC Med Inform Decis Mak, 14, 4. (Read full article)
  44. Barr PJ, Thompson R, Walsh T, Grande SW, Ozanne EM, Elwyn G (2014). The psychometric properties of CollaboRATE: a fast and frugal patient-reported measure of the shared decision-making process. J Med Internet Res, 16(1), e2. (Read full article)
  45. Bravo C, ODonoghue C, Kaplan CP, Luce J, Ozanne E (2014). Can mHealth Improve Risk Assessment in Underserved Populations? Acceptability of a Breast Health Questionnaire App in Ethnically Diverse, Older, Low-Income Women. J Health Dispar Res Pract, 7(4). (Read full article)
  46. Alvarado MD, Conolly J, Park C, Sakata T, Mohan AJ, Harrison BL, Hayes M, Esserman LJ, Ozanne EM (2014). Patient preferences regarding intraoperative versus external beam radiotherapy following breast-conserving surgery. Breast Cancer Res Treat, 143(1), 135-40. (Read full article)
  47. Miron-Shatz T, Hanoch Y, Doniger GM, Omer ZB, Ozanne EM (2014). Subjective but not objective numeracy influences willingness to pay for BRCA1/2 genetic testing among women. Judgm Decis Mak, 9(2), 152-8.
  48. Omer ZB, Hwang ES, Esserman LJ, Howe R, Ozanne EM (2013). Impact of ductal carcinoma in situ terminology on patient treatment preferences. JAMA Intern Med, 173(19), 1830-1. (Read full article)
  49. Elwyn G, Barr PJ, Grande SW, Thompson R, Walsh T, Ozanne EM (2013). Developing CollaboRATE: a fast and frugal patient-reported measure of shared decision making in clinical encounters. Patient Educ Couns, 93(1), 102-7. (Read full article)
  50. Alvarado MD, Mohan AJ, Esserman LJ, Park CC, Harrison BL, Howe RJ, Thorsen C, Ozanne EM (2013). Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer. Ann Surg Oncol, 20(9), 2873-80. (Read full article)
  51. Soeteman DI, Stout NK, Ozanne EM, Greenberg C, Hassett MJ, Schrag D, Punglia RS (2013). Modeling the effectiveness of initial management strategies for ductal carcinoma in situ. J Natl Cancer Inst, 105(11), 774-81. (Read full article)
  52. Trevena LJ, Zikmund-Fisher BJ, Edwards A, Gaissmaier W, Galesic M, Han PK, King J, Lawson ML, Linder SK, Lipkus I, Ozanne E, Peters E, Timmermans D, Woloshin S (2013). Presenting quantitative information about decision outcomes: a risk communication primer for patient decision aid developers. BMC Med Inform Decis Mak, 13 Suppl 2, S7. (Read full article)
  53. Abhyankar P, Volk RJ, Blumenthal-Barby J, Bravo P, Buchholz A, Ozanne E, Vidal DC, Col N, Stalmeier P (2013). Balancing the presentation of information and options in patient decision aids: an updated review. BMC Med Inform Decis Mak, 13 Suppl 2, S6. (Read full article)
  54. Esserman L, Ozanne E, vant Veer L (2013). Will early detection for breast cancer ever work? Clin Chem, 59(1), 190-3. (Read full article)
  55. Ozanne EM, Drohan B, Bosinoff P, Semine A, Jellinek M, Cronin C, Millham F, Dowd D, Rourke T, Block C, Hughes KS (2013). Which risk model to use? Clinical implications of the ACS MRI screening guidelines. Cancer Epidemiol Biomarkers Prev, 22(1), 146-9. (Read full article)
  56. Ozanne EM (2013). Overdiagnosis and Overtreatment of Breast Cancer: How Can We Promote Informed Patient Choice? Curr Breast Cancer Rep, 5(4), 263-5.
  57. Ozanne EM, OConnell A, Bouzan C, Bosinoff P, Rourke T, Dowd D, Drohan B, Millham F, Griffin P, Halpern EF, Semine A, Hughes KS (2012). Bias in the reporting of family history: implications for clinical care. J Genet Couns, 21(4), 547-56. (Read full article)
  58. Lowry KP, Lee JM, Kong CY, McMahon PM, Gilmore ME, Cott Chubiz JE, Pisano ED, Gatsonis C, Ryan PD, Ozanne EM, Gazelle GS (2012). Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis. Cancer, 118(8), 2021-30. (Read full article)
  59. Alvarado M, Ozanne E, Esserman L (2012). Overdiagnosis and overtreatment of breast cancer. Am Soc Clin Oncol Educ Book, e40-5. (Read full article)
  60. Campbell S, Stowe K, Ozanne EM (2011). Interprofessional practice and decision support: an organizational framework applied to a mental health setting. J Interprof Care, 25(6), 423-7. (Read full article)
  61. Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC (2011). Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat, 129(2), 607-16. (Read full article)
  62. Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ (2011). Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat, 129(1), 165-73. (Read full article)
  63. Lee JM, McMahon PM, Kong CY, Kopans DB, Ryan PD, Ozanne EM, Halpern EF, Gazelle GS (2010). Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers. Radiology, 254(3), 793-800. (Read full article)
  64. Ozanne EM, Wittenberg E, Garber JE, Weeks JC (2010). Breast cancer prevention: patient decision making and risk communication in the high risk setting. Breast J, 16(1), 38-47. (Read full article)
  65. Sepucha K, Ozanne EM (2010). How to define and measure concordance between patients' preferences and medical treatments: A systematic review of approaches and recommendations for standardization. Patient Educ Couns, 78(1), 12-23. (Read full article)
  66. Hur C, Broughton DE, Kong CY, Ozanne EM, Richards EB, Truong T, Gazelle GS (2009). Patient preferences for the chemoprevention of colorectal cancer. Dig Dis Sci, 54(10), 2207-14. (Read full article)
  67. Drohan B, Ozanne EM, Hughes KS (2009). Electronic health records and the management of women at high risk of hereditary breast and ovarian cancer. Breast J, 15 Suppl 1, S46-55. (Read full article)
  68. Sepucha KR, Ozanne EM, Partridge AH, Moy B (2009). Is there a role for decision aids in advanced breast cancer? Med Decis Making, 29(4), 475-82. (Read full article)
  69. Ozanne EM, Partridge A, Moy B, Ellis KJ, Sepucha KR (2009). Doctor-patient communication about advance directives in metastatic breast cancer. J Palliat Med, 12(6), 547-53. (Read full article)
  70. Ozanne EM, Loberg A, Hughes S, Lawrence C, Drohan B, Semine A, Jellinek M, Cronin C, Milham F, Dowd D, Block C, Lockhart D, Sharko J, Grinstein G, Hughes KS (2009). Identification and management of women at high risk for hereditary breast/ovarian cancer syndrome. Breast J, 15(2), 155-62. (Read full article)
  71. Braithwaite D, Tammemagi CM, Moore DH, Ozanne EM, Hiatt RA, Belkora J, West DW, Satariano WA, Liebman M, Esserman L (2009). Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer, 124(5), 1213-9. (Read full article)
  72. Ozanne EM, Braithwaite D, Sepucha K, Moore D, Esserman L, Belkora J (2009). Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model. J Clin Oncol, 27(2), 214-9. (Read full article)
  73. Ozanne EM, Drohan B, Hughes KS (2009). Challenges and Improvements in the Identification of Women at High Risk. 20(3), 248-50.
  74. Pandharipande PV, Harisinghani MG, Ozanne EM, Specht MC, Hur C, Lee JM, Gazelle GS (2008). Staging MR lymphangiography of the axilla for early breast cancer: cost-effectiveness analysis. AJR Am J Roentgenol, 191(5), 1308-19. (Read full article)
  75. Hur C, Broughton DE, Ozanne E, Yachimski P, Nishioka NS, Gazelle GS (2008). Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol, 103(10), 2432-42. (Read full article)
  76. Silvia KA, Ozanne EM, Sepucha KR (2008). Implementing breast cancer decision aids in community sites: barriers and resources. Health Expect, 11(1), 46-53. (Read full article)
  77. Ozanne EM, Annis C, Adduci K, Showstack J, Esserman L (2007). Pilot trial of a computerized decision aid for breast cancer prevention. Breast J, 13(2), 147-54. (Read full article)
  78. Sepucha K, Ozanne E, Silvia K, Partridge A, Mulley AG Jr (2007). An approach to measuring the quality of breast cancer decisions. Patient Educ Couns, 65(2), 261-9. (Read full article)
  79. Sepucha K, Ozanne E, Mulley AG Jr (2006). Doing the right thing: systems support for decision quality in cancer care. Ann Behav Med, 32(3), 172-8. (Read full article)
  80. Ozanne EM, Klemp JR, Esserman LJ (2006). Breast cancer risk assessment and prevention: a framework for shared decision-making consultations. Breast J, 12(2), 103-13. (Read full article)
  81. Esserman LJ, Ozanne EM, Dowsett M, Slingerland JM (2005). Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis. Breast Cancer Res, 7(6), R1153-8. (Read full article)
  82. Ozanne EM, Esserman LJ (2004). Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis. Cancer Epidemiol Biomarkers Prev, 13(12), 2043-52. (Read full article)
  83. Esserman L, Sepucha K, Ozanne E, Hwang ES (2004). Applying the neoadjuvant paradigm to ductal carcinoma in situ. Ann Surg Oncol, 11(1 Suppl), 28S-36S. (Read full article)
  84. Holtzman S, Ozanne E, Carone B, Goldstein MK, Steinke G, Timbs J (1999). Decision analysis and Alzheimer disease: three case studies. Genet Test, 3(1), 71-83. (Read full article)

Review

  1. Chung MK, Fagerlin A, Wang PJ, Ajayi TB, Allen LA, Baykaner T, Benjamin EJ, Branda M, Cavanaugh KL, Chen LY, Crossley GH, Delaney RK, Eckhardt LL, Grady KL, Hargraves IG, True Hills M, Kalscheur MM, Kramer DB, Kunneman M, Lampert R, Langford AT, Lewis KB, Lu Y, Mandrola JM, Martinez K, Matlock DD, McCarthy SR, Montori VM, Noseworthy PA, Orland KM, Ozanne E, Passman R, Pundi K, Roden DM, Saarel EV, Schmidt MM, Sears SF, Stacey D, Stafford RS, Steinberg BA, Youn Wass S, Wright JM (2021). Shared Decision Making in Cardiac Electrophysiology Procedures and Arrhythmia Management. [Review]. Circ Arrhythm Electrophysiol, 14(12), e007958. (Read full article)
  2. Torres Roldan VD, Brand-McCarthy SR, Ponce OJ, Belluzzo T, Urtecho M, Espinoza Suarez NR, Toloza FJK, Thota AD, Organick PW, Barrera F, Liu-Sanchez C, Jaladi S, Prokop L, Ozanne EM, Fagerlin A, Hargraves IG, Noseworthy PA, Montori VM, Brito JP (2021). Shared Decision Making Tools for People Facing Stroke Prevention Strategies in Atrial Fibrillation: A Systematic Review and Environmental Scan. [Review]. Med Decis Making, 41(5), 540-549. (Read full article)
  3. Durand MA, Yen RW, OMalley AJ, Schubbe D, Politi MC, Saunders CH, Dhage S, Rosenkranz K, Weichman K, Margenthaler J, Tosteson ANA, Crayton E, Jackson S, Bradley A, Mitchell M, Walling L, Marx C, Volk RJ, Sepucha K, Ozanne E, Percac-Lima S, Bergin E, Goodwin C, Acosta J, Miller C, Harris C, Barth R, Aft R, Feldman S, Cyr AE, Angeles C, Forcino R, Scalia P, Aarts JWM, van den Muijsenbergh M, Jiang S, Elwyn G (2021). [Review]. (Read full article)
  4. Punglia R, Stout N, Cronin A, Uno H, Ozanne E, Hassett M, Frank E, Schrag D, Greenberg C, Soeteman D (2020). [Review]. (Read full article)
  5. Esserman LJ, Shieh Y, Park JW, Ozanne EM (2007). A role for biomarkers in the screening and diagnosis of breast cancer in younger women. [Review]. Expert Rev Mol Diagn, 7(5), 533-44. (Read full article)

Book Chapter

  1. Ozanne EM, Esserman L (2010). Decision Making in Breast Cancer Prevention. In Psicooncología (7, pp. 299-311).

Editorial

  1. Ozanne EM, Noseworthy PA, Cameron KA, Schmidt M, Cavanaugh K, Pershing ML, Guzman A, Sivly A, Fagerlin A (2020). Shared Decision Making in the Era of Telehealth: Implications for Practice and Research. MDM Policy Pract, 5(2), 2381468320976364. (Read full article)

Letter

  1. Ozanne EM, Hwang ES, Esserman LJ (2007). Letter to the Editor [Letter to the editor]. Breast J, 13(5), 540.

Abstract

  1. Alvarado MD, Hayes MT, Sethi R, Ozanne EM (2015). NSABP B-43 is unlikely to produce a cost-effective treatment strategy for HER2+ DCIS [Abstract]. Cancer Res, 75(9 Suppl), P1-10-03.
  2. Ozanne EM, Stout N, Schneider K, Soeteman D, Schrag D, Fordis M, Punglia R (2015). onlineDeCISion.org: An interactive web-based clinical decision aid for DCIS treatment; also presented as a poster at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX [Abstract]. Cancer Res, 75(9 Suppl), P2-10-01.
  3. Thompson C, Ekland M, ODonoghue C, Ozanne EM, Esserman L (2015). The aggregate number of false-positive recalls and biopsies performed under different breast cancer screening strategies in the US; also presented as a poster at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX [Abstract]. Cancer Res, 75(9 Suppl), P3-02-01.
  4. Henderson L, Hubbard R, Wernli K, Kerlikowske K, Buist DSM, Sprague B, Goodrich M, DeMartini W, Ozanne E, Zhu W, ODonoghue C, Virnig BA, Tosteson ANA, Onega T (2015). Are breast density and family history associated with pre-operative breast MRI use? [Abstract]. J Clin Oncol, 33(15 Suppl), e17543.
  5. Ozanne EM, Drohan B, Hughes KS (2013). Breast cancer risk assessment: How risk models can “overdiagnose” risk; also presented at the American Society of Clinical Oncology Annual Meeting Quality Care Symposium; November 1-2, 2013 [Abstract]. Journal of Clinical Oncology, 31(31 Suppl), 184.
  6. Thorsen CM, Weiss JE, Kerlikowske K, Ozanne EM, Buist DS, Hubbard RA, Tosteson AN, Henderson LM, Virnig BA, Goodrich ME, Onega TL (2012). Impact of preoperative MRI on the surgical treatment of breast cancer: a SEER-Medicare analysis [Abstract]. Cancer Res, 72(24 Suppl), P4-01-15.
  7. Howe R, Omer Z, Hanoch Y, Miron-Shatz T, Thorsen C, Ozanne EM (2012). Single nucleotide polymorphism testing for breast cancer risk assessment: Patient trust and willingness to pay [Abstract]. Cancer Res, 72(24 Suppl), P4-11-03.
  8. Thorsen CM, Eklund M, Ozanne EM, Esserman LJ (2012). The cost of mammography screening in the United States by screening policy [Abstract]. Cancer Res, 72(24 Suppl), P3-02-12.
  9. Ozanne EM, Crawford B, Petruse A, Madlensky L, Weiss L, Hogarth M, Wenger N, Goodman D, Park H, Anton-Culver H, Yasmeen S, Howell L, Ojeda H, Parker B, Kaplan C, vant Veer L, Esserman L, Naeim A (2012). Risk assessment and personalized decision support: The University of California Athena Breast Health Network; also presented as a poster at the 35th Annual CTRC‐AACR San Antonio Breast Cancer Symposium; Dec 4‐8, 2012; San Antonio, TX [Abstract]. Cancer Res, 72(24 Suppl), P4-13-13.
  10. Alvarado M, Harrison B, Howe R, Rounds K, Solin L, Ozanne EM (2012). Cost-effectiveness of gene expression profiling for ductal carcinoma in-situ (Oncotype DCIS Score) [Abstract]. Cancer Res, 72(24 Suppl), P5-15-01.
  11. Howe R, Hassett M, Wheelock A, ODonoghue CT, Kaplan C, Ozanne EM (2012). Cost of cancer care: The impact of disclosure on treatment preferences [Abstract]. J Clin Oncol, 30(Suppl 34), 15.
  12. Esserman LJ, Mohan AJ, Park C, Berry D, Ozanne EM, Alvarado MD (2011). Projecting the impact of adopting trial results [Abstract]. Cancer Res, 71(24 Suppl), PD06-08.
  13. Omer Z, Hwang ES, Esserman L, Ozanne EM (2011). Words matter: Influence of DCIS diagnosis terminology on patient treatment decisions [Abstract]. Cancer Res, 71(24 Suppl), P5-15-01.
  14. Ozanne EM, Omer Z, Carlson K (2011). Automated breast cancer risk assessment: Identifying high risk women in the primary care setting; also presented as a poster at the 34th Annual CTRC‐AACR San Antonio Breast Cancer Symposium; Dec 6‐10, 2011; San Antonio, TX [Abstract]. Cancer Res, 71(24 Suppl), P4-10-04.
  15. Alvarado M, Mohan A, Esserman LJ, Ozanne EM (2011). Cost-effectiveness of intraoperative radiation therapy for breast conservation [Abstract]. J Clin Oncol, 29(15 Suppl), 6081.
  16. Ozanne EM, Boortz S, Bechtold T, Esserman LJ (2010). Wide Scale, Automated Breast Cancer Risk Assessment and Decision Support for High Risk Women: www.BreastHealthDecisions.org; also presented as a poster at the 33rd Annual CTRC‐AACR San Antonio Breast Cancer Symposium; Dec 8‐12, 2010; San Antonio, TX [Abstract]. Cancer Res, 70(24 Suppl), P6-09-11.
  17. Esserman E, Chu B, Chung R, Ozanne EM, Yau C, Tsing P, Baehner FL, Tutt AN, Moore DH, Benz C (2010). Risk partitioning model shows need to address time dependence of breast cancer recurrence™ [Abstract]. J Clin Oncol, 28(15 Suppl), 10605.
  18. Ozanne EM, Cipriano L, Cameron M, Newman T, Esserman LJ (2009). Cost-effectiveness of surgical interventions for BRCA gene mutation carriers: impact of delaying decision-making; also presented as a poster at the 2008 CTRC-AACR San Antonio Breast Cancer Symposium [Abstract]. Cancer Res, 69(2 Suppl), 503.
  19. Ozanne EM, Cipriano L, Cameron M, Newman T, Esserman LJ (2009). Cost-effectiveness of genetic testing for BRCA1 and BRCA2 mutations; also presented as a poster at the 2008 CTRC-AACR San Antonio Breast Cancer Symposium [Abstract]. Cancer Res, 69(2 Suppl), 6100.
  20. Ozanne EM, Sharko J, Drohan B, Grinstein G, Hughes KS (2009). Identification of high-risk lesions through automated natural language processing (NLP) of pathology reports; also presented as a poster at the 2008 CTRC-AACR San Antonio Breast Cancer Symposium [Abstract]. Cancer Res, 69(2 Suppl), 3001.
  21. Braithwaite D, Moore D, Liebman M, Belkora J, West D, Satariano W, Ozanne EM, Esserman (2006). New comorbidity model to optimize decisions about interventions for breast cancer patients [Abstract]. Breast Cancer Res Treat, 100(Suppl 1).
  22. Braithwaite D, Moore D, West D, Satariano W, Liebman M, Belkora J, Ozanne EM, Esserman L (2005). Estimating prognostic impact of comorbidity: Development of a breast cancer specific model [Abstract]. Breast Cancer Res Treat, 94(Suppl 1).
  23. Ozanne EM, Esserman L (2003). A new breast cancer prevention tool incorporates contextual risk assessment and biomarkers [Abstract]. J Clin Oncol.
  24. Ozanne EM, Esserman L (2001). Risk Assessment Guidelines for Breast Cancer Prevention Used in a Shared Medical Decision Making Setting; also presented orally at the 23rd Annual Meeting of the Society for Medical Decision Making [Abstract]. Med Decis Making, 21(6).

Other

  1. Rogers AM, Lauren BN, Woo Baidal JA, Ozanne EM, Hur C (2021). Corrigendum to "Persistent effects of the COVID-19 pandemic on diet, exercise, risk for food insecurity, and quality of life: A longitudinal study among U.S. adults" [Appetite 167 (2021) 105639]. Appetite (168, p. 105701). England. (Read full article)
  2. Ozanne EM (2003). An analytic approach to medical risk management: Decisions for breast cancer prevention. (Thesis). Stanford, CA: Stanford University.